(S)-Carvedilol, the S-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (S)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX)In VitroThe β-receptor blocking activity of (S)-Carvedilol is about 100
(S)-Carvedilol, the S-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (S)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX)In VitroThe β-receptor blocking activity of (S)-Carvedilol is about 100
(S)-Carvedilol, the S-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (S)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX)In VitroThe β-receptor blocking activity of (S)-Carvedilol is about 100
(S)-Carvedilol, the S-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (S)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX)In VitroThe β-receptor blocking activity of (S)-Carvedilol is about 100
(S)-Carvedilol, the S-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (S)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX)In VitroThe β-receptor blocking activity of (S)-Carvedilol is about 100
(S)-Carvedilol, the S-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (S)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX)In VitroThe β-receptor blocking activity of (S)-Carvedilol is about 100
InformationONO-4059 analogue ONO-4059 analogue (ONO-WG-307) is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.TargetsBTK 23.9 nMIn vitroIn TMD-8 cells, ONO-4059 inhibits cell growth
InformationONO-4059 analogue ONO-4059 analogue (ONO-WG-307) is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.TargetsBTK 23.9 nMIn vitroIn TMD-8 cells, ONO-4059 inhibits cell growth
InformationONO-4059 analogue ONO-4059 analogue (ONO-WG-307) is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.TargetsBTK 23.9 nMIn vitroIn TMD-8 cells, ONO-4059 inhibits cell growth
InformationONO-4059 analogue ONO-4059 analogue (ONO-WG-307) is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.TargetsBTK 23.9 nMIn vitroIn TMD-8 cells, ONO-4059 inhibits cell growth
InformationONO-4059 analogue ONO-4059 analogue (ONO-WG-307) is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.TargetsBTK 23.9 nMIn vitroIn TMD-8 cells, ONO-4059 inhibits cell growth
InformationONO-4059 analogue ONO-4059 analogue (ONO-WG-307) is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.TargetsBTK 23.9 nMIn vitroIn TMD-8 cells, ONO-4059 inhibits cell growth
InformationONO-4059 analogue ONO-4059 analogue (ONO-WG-307) is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.TargetsBTK 23.9 nMIn vitroIn TMD-8 cells, ONO-4059 inhibits cell growth
InformationONO-4059 analogue ONO-4059 analogue (ONO-WG-307) is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.TargetsBTK 23.9 nMIn vitroIn TMD-8 cells, ONO-4059 inhibits cell growth
InformationONO-4059 analogue ONO-4059 analogue (ONO-WG-307) is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.TargetsBTK 23.9 nMIn vitroIn TMD-8 cells, ONO-4059 inhibits cell growth
InformationONO-4059 analogue ONO-4059 analogue (ONO-WG-307) is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.TargetsBTK 23.9 nMIn vitroIn TMD-8 cells, ONO-4059 inhibits cell growth